ArticlePloS one2013
Lower ADD1 gene promoter DNA methylation increases the risk of essential hypertension.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Accelerated epigenetic age in hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Pooled it
- The role of DNA methylation and histone modifications in blood pressure: a systematic review.Journal of human hypertension · 2019Pooled it
- The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis.PloS one · 2014Pooled it
- Epigenetic Changes Related to Hypertension in Asian Adults: A Systematic Review.Chronic diseases and translational medicine · 2025Review
- Epigenetic Mechanisms Involved in Inflammaging-Associated Hypertension.Current hypertension reports · 2022Review
- Predicting High Blood Pressure Using DNA Methylome-Based Machine Learning Models.Biomedicines · 2022Article
- Comprehensive molecular characterization of hypertension-related genes in cancer.Cardio-oncology (London, England) · 2022Article
- Novel methylation mark and essential hypertension.Journal, genetic engineering & biotechnology · 2022Review
- Article
- The Association between Gly460Trp-Polymorphism of Alpha-Adducin 1 Gene (International journal of hypertension · 2021Article
- Roles and Mechanisms of DNA Methylation in Vascular Aging and Related Diseases.Frontiers in cell and developmental biology · 2021Review
- DNA NAging · 2020Article
- Hypermethylation of dihydrofolate reductase promoter increases the risk of hypertension in Chinese.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020Article
- Epigenetic modification: a regulatory mechanism in essential hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Review
- Functional relevance of promoter CpG island of human Angiotensin II type 1 receptor (AT1R) gene.Molecular and cellular biochemistry · 2019Article
- CBS promoter hypermethylation increases the risk of hypertension and stroke.Clinics (Sao Paulo, Brazil) · 2019Article
- Serine hydroxymethyltransferase 1 promoter hypermethylation increases the risk of essential hypertension.Journal of clinical laboratory analysis · 2019Article
- Epigenetic Biomarkers in Cardiovascular Diseases.Frontiers in genetics · 2019Review
- Unexpected role of the human cytomegalovirus contribute to essential hypertension in the Kazakh Chinese population of Xinjiang.Bioscience reports · 2018Article
- DNA Methylation and Histone Modification in Hypertension.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of our study is to investigate the contribution of promoter DNA methylation of α-adducin (ADD1) gene to the risk of essential hypertension (EH). Using the bisulphite pyrosequencing technology, DNA methylation levels of five CpG dinucleotides on ADD1 promoter were measured among 33 EH cases and 28 healthy controls. Significantly higher ADD1 DNA methylation levels were observed in the females than in the males (CpG1: P = 0.016; CpG2-5: P = 0.021). A breakdown analysis by gender showed that lower CpG1 methylation was associated with an increased risk of EH in females (adjusted P = 0.042). A much more significant association between lower CpG2-5 methylation levels and the increased risk of EH was found in males (adjusted P = 0.008). CpG1 methylation was inversely correlated with age in females (r = -0.407, P = 0.019) but not in males. ADD1 CpG1 and CpG2-5 methylation levels were significantly lower in post-menopausal (>50 years) women than pre-menopausal (≤50 years) women (CpG1: P = 0.006; CpG2-5: P = 0.034). A significant interaction between CpG1 methylation and age was found in females (CpG1*age: P = 0.029). CpG2-5 methylation was shown as a significant predictor of EH in males [area under curve (AUC) = 0.855, P = 0.001], in contrast that CpG1 methylation was a trend toward indicator in females (AUC = 0.699, P = 0.054). In addition, significant differences were observed between males and females for alanine aminotransferase (ALT, P = 0.001), aspartate aminotransferase (AST, P = 0.005) and uric acid (P<0.001). The concentration of AST was inversely correlated with ADD1 CpG2-5 methylation levels in female controls (r = -0.644, P = 0.024). These observations may bring new hints to elaborate the pathogenesis of EH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.